AUPH MEXC RealStocks
Own real AUPH shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:48:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aurinia Pharmaceuticals Inc. (AUPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.13, with a market capitalization of $2.06B and a P/E ratio of 6.57. Over the past 52 weeks, its price has ranged from $13.52 to $19.25. This page covers its latest market performance, valuation, price trends and company information.
$2.06B | |
$15.30 | |
$15.53 | |
$15.06 | |
$15.40 | |
598.61K | |
855.67K | |
6.57 | |
$19.25 | |
$13.52 | |
-- | |
2026-09-30 |
Aurinia Pharmaceuticals Inc. (AUPH) last closed at $15.13 as of 2026-11-19 00:31:00, down 1.72% ($0.27) from the previous close of $15.40.
During the latest regular trading session, AUPH traded between $15.06 and $15.53, with a volume of 598.61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Aurinia Pharmaceuticals Inc. (AUPH) moved from $16.30 to $15.13, representing a decline of 7.15% ($1.17).
The stock traded between $15.05 and $16.68 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 891.48 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.2%
AUPH is currently trading at $15.13, placing it 28.2% of the way from its 52-week low of $13.52 to its 52-week high of $19.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aurinia Pharmaceuticals Inc. (AUPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AUPH, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AUPH shares and USD.
AUPH Shares to USD
1.00 AUPH shares = 15.134 USD
Calculations are estimates based on the latest available price and are for reference only.